Previous 10 | Next 10 |
Immutep (IMMP) -14% after expands the evaluation of efti into a triple combination therapy of efti, chemotherapy and anti-PD-1 therapyAshford Hospitality Trust (AHT) -10% after inks stock purchase agreement with Seven Knots.BIT Mining (BTCM) -9%.Riot Blockchain (RIOT) -8%....
Sydney, AUSTRALIA, June 21, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( I mmutep or C ompany ), is pleased to announce that it has received commitments for a A$60 million two-tranche private placement of new ordinary shares ( New Sha...
New Phase I clinical trial, called INSIGHT-003, in patients with various solid tumours Expands the evaluation of efti into a triple combination therapy of efti, chemotherapy and anti-PD-1 therapy First patient in expected in Q3 of calendar year 2021, with initial interim results e...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips It can be very boring to play it safe 100% of the time. Especially in these times when undisciplined investing seems to be all the rage. And even though some of the current investing trends can seem downright unbelievable,...
Immutep ([[IMMP]]) provides an update on its preclinical development pipeline. Under the collaboration commenced in 2019 with Cardiff University, the Company has advanced the discovery and development of a new generation of small molecule anti-LAG-3 therapies with an aim to make oral treatmen...
SYDNEY, AUSTRALIA, June 08, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), the leading developer of LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to provide an update on its ...
Combination therapy with eftilagimod alpha and pembrolizumab demonstrates very favourable overall response rate (ORR) together with favourable duration and depth of responses in 1 st line NSCLC (41.7%, 2 CRs; minimum DoR > 6 months) and 2 nd line HNSCC (29.7% ORR, 5 CRs; minimu...
Encouraging activity signals from the combination of efti and avelumab with a response rate of 41.7% in different solid tumours (DCR 50%) acc. to RECIST 1.1 No selection of patients for immunogenic markers (e.g. PD-L1 expression levels, MSI high or TMB) 9 out of 12 patients still ...
BriaCell Therapeutics (BCTX) +102% after update on the overall survival data of advanced breast cancer patients.Constellation Pharmaceuticals (CNST) +67% on merger agreement with MorphoSys.Stealth BioTherapeutics (MITO) +46% on EMA orphan drug status for elamipretide.AC Immune ...
SYDNEY, AUSTRALIA, June 02, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of p...
News, Short Squeeze, Breakout and More Instantly...
Media Release Study expected to enrol first participants during Q3 CY2024 SYDNEY, AUSTRALIA, July 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing no...
2024-07-12 10:45:04 ET QuantumScape Corp (QS) QS is trading UP for the last 5 days, and it at trading at $7.84 with volume of 22,322,158 and a one day change of $0.78 (10.98%). QuantumScape Corp has a 52-week low of 4.67 and a 52-week high of $13.86. The business's 50-day moving ave...
Media Release Efti in combination with KEYTRUDA® (pembrolizumab) achieved a 35.5% response rate in evaluable patients (N=31), according to RECIST 1.1, among the highest recorded for a treatment approach not containing chemotherapy in patients with CPS <1 High complete response...